Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 9, 2023
Reporting Period: Event-based report regarding an accelerated share repurchase agreement executed on November 9, 2023.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. It focuses exclusively on capital allocation activities.
- Share Repurchase Authorization: $100 million program authorized in January 2023.
- ASR Transaction Size: $25 million.
- Initial Shares Delivered: Approximately 865,426 shares.
- Reference Stock Price: $23.11 (Closing price on November 8, 2023).
- Initial Delivery Percentage: Approximately 80% of expected total shares under the ASR.
- Shares Outstanding (as of Sept 30, 2023): Approximately 33.1 million.
Material Changes
The primary material change is the execution of an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC. This transaction reduces the company's cash by $25 million and reduces the number of outstanding shares, subject to final settlement adjustments based on volume-weighted average prices.
Guidance, Outlook, and Risks
Outlook and Settlement: The final settlement of the ASR Agreement is expected to be completed in the fourth quarter of 2023. The final number of shares repurchased will be determined by the volume-weighted average price of the stock during the term of the agreement.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ due to securities market developments, fluctuations in trading volume, and changes in the market price of the Company's common stock. The Company assumes no obligation to update these statements.
Investor Verification Checklist
- Verify the final settlement date and total share count upon completion of the ASR in Q4 2023.
- Confirm the remaining balance of the $100 million share repurchase program after this $25 million transaction.
- Review the impact of the $25 million cash outflow on the company's liquidity position in the next quarterly report (10-Q).
- Monitor the volume-weighted average price (VWAP) of the stock during the ASR term to estimate the final share count.